Maxim Group Initiates Coverage On INVO Bioscience with Buy Rating, Announces Price Target of $7
Maxim Group analyst Jason McCarthy initiates coverage on INVO Bioscience (NASDAQ:INVO) with a Buy rating and announces Price Target of $7.
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences.
INVO Bioscience Highlights 4 Poster Abstracts On INVOcell Presented At American Society For Reproductive Medicine Congress
INVO Bioscience, Inc. (NASDAQ:INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients
4 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
INVO Bioscience Earnings Perspective: Return On Capital Employed
INVO Bioscience (NASDAQ:INVO) brought in sales totaling $208.47 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 20.95%, resulting in a loss of $1.89 million.
INVO Bioscience Announces $4M Registered Direct Offering, 1.2M Shares At $3.26/Share
INVO Bioscience, Inc. (NASDAQ:INVO), a medical device company focused on commercializing the world's only in vivo culture system (IVC), INVOcell®, today announced that it has entered into definitive
Roth Capital Maintains Buy on INVO Bioscience, Lowers Price Target to $5.25
Roth Capital analyst Scott Henry maintains INVO Bioscience (NASDAQ:INVO) with a Buy and lowers the price target from $5.75 to $5.25.
INVO Bioscience Q2 Net Loss ~$1.8M, Adj. EBITDA Loss $1.3M, Sales $208.47K Miss $410.00K Estimate
INVO Bioscience (NASDAQ:INVO) reported quarterly sales of $208.47 thousand which missed the analyst consensus estimate of $410.00 thousand by 49.15 percent.
Earnings Scheduled For August 16, 2021
Companies Reporting Before The Bell
• Entera Bio (NASDAQ:ENTX) is likely to report earnings for its second quarter.
• Data Storage (NASDAQ:DTST) is expected to report earnings for its second quarter.